AZD 5363

Drug Profile

AZD 5363

Alternative Names: AZD-5363

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
  • Developer Astex Therapeutics; AstraZeneca; Cancer Research Technology; Conquer Cancer Foundation; Netherlands Cancer Institute; Royal Marsden NHS Foundation Trust; Samsung Medical Center; The Institute of Cancer Research; University of Nottingham; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Prostate cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Apr 2017 Adverse events and pharmacodynamics data from a preclinical trial in Prostate cancer presented at the 108th annual meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Jan 2017 AstraZeneca completes a phase II trial in Breast cancer (Combination therapy, Late-stage disease, Mid-stage disease) in Hungary, France and United Kingdom (PO) (NCT02423603) (EudraCT2013-001521-43)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top